Meanwhile, nivolumab is being evaluated in the ANVIL trial (NCT02595944), part of the ALCHEMIST platform, which targets patients with resected NSCLC who are not eligible for EGFR or ALK-directed therapies. Here, ALK is linked to non-small cell lung carcinoma.